Please wait a minute...
Reviews in Cardiovascular Medicine  2012, Vol. 13 Issue (4): 150-160     DOI: 10.3909/ricm0614
Review Previous articles | Next articles
Hospital-Acquired Anemia in Patients With Cardiovascular Disease: Incidence, Outcomes, and Opportunities for Prevention
Adam C. Salisbury, Mikhail Kosiborod
Saint Luke's Mid America Heart and Vascular Institute, Kansas City, MO; University of Missouri-Kansas City School of Medicine, Kansas City, MO
Download:  PDF(240KB)  ( 112 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
Anemia is well recognized as a marker of poor prognosis in patients with cardiovascular disease. Despite increasing awareness that anemia is associated with higher mortality, more frequent hospitalization, and worse health status, it remains unclear whether treating chronic anemia improves patients’ outcomes. The importance of studying hospital-acquired anemia (HAA), and recognizing which patients are at high risk for developing HAA early in the course of their hospitalization, is underscored by the potential opportunities for HAA prevention and management. This article reviews the incidence of HAA, risk factors for developing HAA, and its relationship with clinical outcomes.
Key words:  Hospital-acquired anemia      Cardiovascular disease      Acute myocardial infarction      Clinical outcomes     
Published:  30 December 2012     

Cite this article: 

Adam C. Salisbury, Mikhail Kosiborod. Hospital-Acquired Anemia in Patients With Cardiovascular Disease: Incidence, Outcomes, and Opportunities for Prevention. Reviews in Cardiovascular Medicine, 2012, 13(4): 150-160.

URL: 

https://rcm.imrpress.com/EN/10.3909/ricm0614     OR     https://rcm.imrpress.com/EN/Y2012/V13/I4/150

[1] Shanna J. Hardin, Mahavir Singh, Wintana Eyob, Jack C. Molnar, Rubens P. Homme, Akash K. George, Suresh C. Tyagi. Diet-induced chronic syndrome, metabolically transformed trimethylamine-N-oxide, and the cardiovascular functions[J]. Reviews in Cardiovascular Medicine, 2019, 20(3): 121-128.
[2] Wenyan Jiang, Mei Wang. New insights into the immunomodulatory role of exosomes in cardiovascular disease[J]. Reviews in Cardiovascular Medicine, 2019, 20(3): 153-160.
[3] Rudaynah A. Alali. A short review of proprotein convertase subtilisin/kexin type 9 inhibitors[J]. Reviews in Cardiovascular Medicine, 2019, 20(1): 1-8.
[4] Jennifer G. Robinson, Karol E. Watson. Identifying Patients for Nonstatin Therapy[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 1-8.
[5] Davide Bolignano, Anna Pisano, Graziella D’Arrigo. Pulmonary hypertension: a neglected risk condition in renal patients?[J]. Reviews in Cardiovascular Medicine, 2018, 19(4): 117-121.
[6] Peter A. McCullough, Aaron Y. Kluger, Kristen M. Tecson, Clay M. Barbin, Andy Y. Lee, Edgar V. Lerma, Zachary P. Rosol, Sivan L. Kluger, Janani Rangaswami. Inhibition of the Sodium–Proton Antiporter (Exchanger) is a Plausible Mechanism of Potential Benefit and Harm for Drugs Designed to Block Sodium Glucose Co-transporter 2[J]. Reviews in Cardiovascular Medicine, 2018, 19(2): 51-63.
[7] Alberto Palazzuoli, Helen Hashemi, Lauren C. Jameson, Peter A. McCullough. Hyperuricemia and Cardiovascular Disease[J]. Reviews in Cardiovascular Medicine, 2017, 18(4): 134-145.
[8] Claudio Ronco, Federico Ronco, Peter A. McCullough. A Call to Action to Develop Integrated Curricula in Cardiorenal Medicine[J]. Reviews in Cardiovascular Medicine, 2017, 18(3): 93-99.
[9] Boback Ziaeian, John Dinkler, Karol Watson. Implementation of the 2013 American College of Cardiology/American Heart Association Blood Cholesterol Guideline Including Data From the Improved Reduction of Outcomes: Vytorin Efficacy International Trial[J]. Reviews in Cardiovascular Medicine, 2015, 16(2): 125-130.
[10] Norman E. Lepor, Dean D. Fouchia, Peter A. McCulloughsup. New Vistas for the Treatment of Obesity: Turning the Tide Against the Leading Cause of Morbidity and Cardiovascular Mortality in the Developed World[J]. Reviews in Cardiovascular Medicine, 2014, 15(S2): 1-21.
[11] Virginia A. Triant. Epidemiology of Coronary Heart Disease in Patients With Human Immunodeficiency Virus[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 1-8.
[12] Patrick W.G. Mallon. Impact of Nucleoside Reverse Transcriptase Inhibitors on Coronary Heart Disease[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 21-29.
[13] Norman E. Lepor, Laurn Contreras, Chirag Desai, Dean J. Kereiakes. The Potential Role of Anti-PCSK9 Monoclonal Antibodies in the Management of Hypercholesterolemia[J]. Reviews in Cardiovascular Medicine, 2014, 15(4): 290-309.
[14] Karol E. Watson, Eric H. Stocker, Douglas S. Jacoby, Peter A. McCullough. Advanced Lipid Testing: When, Why, and In Whom?[J]. Reviews in Cardiovascular Medicine, 2014, 15(4): 310-319.
[15] Sabas I. Gomez, Pablo Urbandt, Nirat Beohar, Orlando Santana. Renal Denervation: Current Status and Future Applications[J]. Reviews in Cardiovascular Medicine, 2014, 15(4): 351-357.
No Suggested Reading articles found!